My latest Clinical Pipeline column at #NatureMedicine is just out.
This was an interesting piece for me, to see what's going with drugs targeting #TGFbeta family molecules in a clinical setting, in this case an activin receptor 2a/IgG1 Fc domain fusion protein selectively mopping up ligands. The drug's been through trials in oncology, thalassemia & other conditions, but it looks like it had a good hit in pulmonary arterial #hypertension.
@cyrilpedia As a non-clinician, I found this one very interesting, partly because of the discussion of disease mechanism
